Thalidomide treatment reduces colon injury induced by experimental colitis

Shock

Volumn 23, Issue 6, 2005, Pages 556-564

  Mazzon, Emanuela ^a   Muià, Carmelo ^a   Di Paola, Rosanna ^a   Genovese, Tiziana ^a   De Sarro, Angelina ^a   Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Colitis; ICAM 1; Inflammatory infiltration; PARP; Thalidomide

Indexed keywords

3 NITROTYROSINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NITROBENZENE DERIVATIVE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); SULFONIC ACID DERIVATIVE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FILTRATION; COLITIS; COLON INJURY; COLON MUCOSA; CROHN DISEASE; CYTOKINE PRODUCTION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NECROSIS; NEUTROPHIL; NONHUMAN; TISSUE LEVEL; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; COLITIS; COLON; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; MICE; NEUTROPHILS; PEROXIDASE; POLY ADENOSINE DIPHOSPHATE RIBOSE; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 18744416547     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000163385.12490.9d     Document Type: Article

References (75)

1. Romagnani S: Th1/Th2 cells. Inflamm Bowel Dis 5:285-294, 1999.
2. Groux H, O'Garra A, Bigler M: A CD4 T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389:737-742, 1997.
3. Cottrez F, Hurst SD, Coffman RL, Groux H: T regulatory cells inhibit a Th2-specific response in vivo. J Immunol 165:4848-4853, 2000.
4. Butcher EC, Picker LJ: Lymphocyte homing and homeostasis. Science 272:60-66, 1996.
5. Papadakis KA, Targan SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119:1148-1157, 2000.
6. Barnes PJ, Karin M: Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071, 1997.
7. Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182-205, 1998.
8. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deern RL, Shealy D, Targan SR: A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159:6276-6282, 1997.
9. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261-1270, 1996.
10. Takazoe M, Tanaka T, Kondo K, Ichimori T, Shinoda T: The present status and recent development of the treatment for inflammatory bowel diseases: desirable effect of extracorporeal immunomodulation. Ther Apher 6:305-311, 2002.
11. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF: Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 113:118-126, 1997.
12. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314, 1994.
13. + T cells. J Immunol 158:2099-2106, 1997.
14. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276:3222-3230, 2001.
15. Isner JM, Losordo DW: Therapeutic angiogenesis for heart failure. Nat Med 5:491-492, 1999.
16. Ferrara N: Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:C1358-C1366, 2001.
17. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K: VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 96:822-828, 2001.
18. Bousvaros A, Leichtner A, Zurakowski D, Kwon J, Law T, Keough K, Fishman S: Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease. Dig Dis Sci 44:424-430, 1999.
19. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163:380-386, 1999.
20. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G, Karp CL: Inhibition of IL-12 production by thalidomide. J Immunol 159:5157-5161, 1997.
21. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB: Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117:1271-1277, 1999.
22. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 117:1278-1287, 1999.
23. Lienenluke B, Stojanovic T, Fiebig T, Fayyazi A, Germann T, Hecker M: Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat: role of endothelial cell-leukocyte interaction. Br J Pharmacol 133:1414-1423, 2001.
24. Miller MJ, Thompson JH, Zhang XJ, Sadowska-Krowicka H, Kakkis JL, Munshi UK, Sandoval M, Rossi JL, Eloby-Childress S, Beckman JS: Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 109:1475-1483, 1995.
25. Lora L, Mazzon E, Billington D, Milanesi C, Naccarato R, Martines D: Effects of cyclosporin A on paracellular and transcellular transport of horseradish peroxidase in perfused rat livers. Dig Dis Sci 42:514-521, 1997.
26. Wallace JL, Keenan CM, Gale D, Shoupe TS: Exacerbation of experimental colitis by non-steroidal anti-inflammatory drugs is not related to elevate leukotriene B4 synthesis. Gastroenterology 102:18-27, 1992.
27. Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP: Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 39:150-156, 1993.
28. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157-167, 1985.
29. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156:2169-2177, 2000.
30. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989.
31. Wettstein AR, Meagher AP: Thalidomide in Crohn's disease. Lancet 350:1445-1446, 1997.
32. McBride WG: Thalidomide and congenital abnormalities. Lancet 11:1958-1960, 1961.
33. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173:699-703, 1991.
34. Holm AL, Bowers KE, McMeekin TO, Gaspari AA: Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 129:1548-1550, 1993.
35. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055-1058, 1992.
36. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O: Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 16:158-163, 1989.
37. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H: Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443-450, 1998.
38. Becker R, Frankus E, Graudums I, Gunzler WA, Helm FC, Flohe L: The metabolic fate of supidimide in the rat. Arzneimittelforschung 32:1101-1111, 1982.
39. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E: The effect of thalidomide and two analogs on collagen-induced arthritis. J Rheumatol 25:964-969, 1998.
40. Carty E, De Brabander M, Feakins RM, Rampton DS: Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 46:487-492, 2000.
41. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T: Crohn's disease is associated with novel polymorphisms in the 5¢-flanking region of the tumor necrosis factor gene. Gastroenterology 117:1062-1068, 1999.
42. Reimund JM, Dumont S, Muller CD, Kenney JS, Kedinger M, Baumann R, Poindron P, Duclos B: in vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40:475-480, 1997.
43. Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S: Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40:470-474, 1997.
44. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J: Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7:251-259, 1995.
45. Bauditz J, Wedel S, Lochs H: Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50:196-200, 2002.
46. Marriott JB, Westby M, Cookson S, Guckian M, Goodbourn S, Muller G, Shire MG, Stirling D, Dalgleish AG: CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 161:4236-4243, 1998.
47. Oliver SJ, Freeman SL, Corral LG, Ocampo CJ, Kaplan G: Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol 118:315-321, 1999.
48. Mulligan MS, Polley MJ, Bayer RJ: Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest 90:1600-1607, 1992.
49. Davenpeck KL, Gauthier TW, Albertine KH: Role of P-selectin in microvascular leukocyte-endothelial interaction in splanchnic ischemia-reperfusion. Am J Physiol 267:H622-H630, 1994.
50. Farhood A, McGuire GM, Manning AM: Intercellular adhesion molecule 1 (ICAM-1) expression and its role in neutrophil-induced ischemia-reperfusion injury in rat liver. J Leukocyte Biol 57:368-374, 1995.
51. Shreeniwas R, Koga S, Karakurum M: Hypoxia-mediated induction of endothelial cell interleukin-1 alpha. An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J Clin Invest 90:2333-2339, 1992.
52. + T lymphocytes on tumor necrosis factor α-activated vascular endothelium under flow. J Exp Med 181:1179-1186, 1995.
53. Clark WM, Lauten JD, Lessov N: Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Mol Chem Neuropathol 26:213-230, 1995.
54. Horie Y, Wolf R, Iyasaka M: Leukocyte adhesion and hepatic microvascular responses to intestinal ischemia/reperfusion in rats. Gastroenterology 111:666-673, 1996.
55. Zingarelli B, Szabo C, Salzman AL: Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 116:335-345, 1999.
56. Cuzzocrea S, McDonald MC, Mazzon E: Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut 48:478-488, 2001.
57. Shiratora Y, Aoki S, Takada H: Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestion 44:163-171, 1989.
58. Lefer AM, Lefer DJ: Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33:71-90, 1993.
59. Grisham MB: Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859-861, 1994.
60. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, Podolsky DK: Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 105:1681-1688, 1993.
61. Halliwell B: What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett 411:157-160, 1997.
62. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A: Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391:393-397, 1998.
63. Zingarelli B, Szabò C, Salzman AL: Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 45:199-209, 1999.
64. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF: Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 111:871-885, 1996.
65. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87:1620-1624, 1990.
66. Ischiropoulos H, Zhu L, Beckman JS: Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 298:446-451, 1992.
67. Szabo C, Dawson VL: Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 19:287-298, 1998.
68. Szabo C, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, Salzman AL, Perretti M: Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J Exp Med 186:1041-1049, 1997.
69. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58:169-174, 2000.
70. Verheul HM, Hoekman K, Luykx-de Bakker S, Eckman CA, Folman CC, Broxterman HJ, Pinedo HM: Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187-2190, 1997.
71. Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF: in vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol 275:H1054-H1061, 1998.
72. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94:395-404, 1998.
73. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE, Kouroumalis EA: Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 96:776-781, 2001.
74. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP: Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156:1733-1739, 2000.
75. Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, Klagsbrun M, Ferrara N, Bussolino F: Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 273:22128-22135, 1998.